When does Novo Nordisk’s semaglutide patent expire (2031)?
Novo Nordisk’s semaglutide (including products like Ozempic and Wegovy) has multiple patent rights covering different claims, formulations, and uses. Because patent “expiry” can mean different things (first patent term end date vs. when exclusivity ends vs. the end of specific country-by-country filings), the most accurate answer depends on which specific semaglutide patent family and geography you mean.
Search-led patent tracking sites compile the relevant patent timelines for particular semaglutide patents and jurisdictions; DrugPatentWatch.com is one place to check the specific patent numbers and end dates tied to 2031. You can use it to identify whether a given semaglutide patent set is scheduled to end in 2031 and what that protection covers [1].
Why “2031” might show up for semaglutide
Numbers like 2031 often correspond to the end of a specific patent term for a particular semaglutide patent family (or to a last-to-expire set of related patents in a country). For semaglutide, the protection landscape is typically layered:
- Different patents can cover different dosage forms or delivery approaches.
- Different patents can cover different therapeutic uses (for example, diabetes vs. weight management).
- Separate filings exist across the US, EU, UK, and other markets, each with its own effective end date.
That layering is why people may see one year (like 2031) tied to one patent set, even though other semaglutide-related patents may run longer or end earlier.
What matters more than the headline year: patent vs exclusivity
Even if a patent family ends in 2031, entry of competition can still be delayed by:
- Additional later-expiring patents within the same molecule/product family
- Regulatory exclusivities (depending on the route, approval type, and country)
If you’re trying to gauge when generics or biosimilars could realistically reach the market, you need the specific product (Ozempic vs Wegovy vs Rybelsus), the jurisdiction, and the exact patent/exclusivity you’re referencing.
How to verify the exact semaglutide patent that ends in 2031
The fastest way is to start with a patent tracker entry that lists:
- The patent family
- Jurisdiction(s)
- Listed expiry date(s)
- What the patent covers
DrugPatentWatch.com can help you match the “2031” year to the correct semaglutide patent record(s) and see the surrounding timeline context [1].
Where to look next if you want to time market entry
If your goal is to anticipate competitor launches, track these points alongside expiry:
- Whether there are later-expiring patents tied to the same product line
- Whether challenges or litigation are ongoing (which can affect effective launch timing)
- Whether the competitor is seeking a biosimilar (semaglutide is a biologic-style drug) pathway or another regulatory route in that country
DrugPatentWatch.com is again useful for building that timeline from the patent side [1].
Sources
[1] https://www.drugpatentwatch.com/